Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$1.5B
58M shares
52-week range
$4.30 – $40.37
54% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.40%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.7M | $1.0M | $310.3K | $244.9K | $2.6M | $25.2M | $22.3M | $0 |
| Cost of revenue | $0 | $5.1M | $0 | $0 | $21.8M | $36.4M | $50.0M | $0 |
| Gross profit | $1.7M | −$4.1M | $310.3K | $244.9K | −$19.3M | −$11.3M | −$27.7M | $0 |
| Gross margin | 100.0% | -411.6% | 100.0% | 100.0% | -755.1% | -44.8% | -124.4% | — |
| R&D | $12.1M | $5.1M | $8.5M | $13.6M | $21.8M | $36.4M | $50.0M | $84.5M |
| Operating income | −$15.3M | −$7.7M | −$13.7M | −$20.9M | −$29.7M | −$24.1M | −$42.6M | −$108.1M |
| EBITDA | −$15.2M | −$7.6M | −$13.5M | −$19.8M | −$28.5M | −$21.2M | −$39.0M | −$100.1M |
| Net income | −$15.2M | −$7.6M | −$13.7M | −$20.0M | −$29.0M | −$22.3M | −$40.5M | −$105.0M |
| Net margin | -909.1% | -760.4% | -4401.9% | -8175.9% | -1137.4% | -88.5% | -181.7% | — |
| EPS (diluted) | -5.17 | -2.06 | -0.88 | -0.87 | -1.18 | -0.83 | -1.15 | -2.26 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $131M | $-0.23 | $-1.19–$0.81 | 8 |
| 2027 | $117M | $-0.69 | $-2.43–$0.59 | 7 |
| 2028 | $321M | $2.11 | $0.60–$5.04 | 4 |
| 2029 | $451M | $3.57 | $-0.77–$9.13 | 2 |
Forward consensus · source: Financial Modeling Prep
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
www.capricor.comNo one on the platform currently holds CAPR.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2024-06-30 | 137,500 | $655.9K |
| Execution date | Ratio |
|---|---|
| 2019-06-05 | 1-for-10reverse |
| 2005-04-05 | 1-for-20reverse |
No one on the platform has traded CAPR yet.
| +2.30% |
| $507M |
| — |
| EDITEditas Medicine, Inc. | $3.20 | +12.28% | $313M | — |
| IMMPImmutep Limited | $0.41 | +4.38% | $60M | — |
Source: Financial Modeling Prep · peers by sector/industry
Trading at 43.6× sales vs its 27.5× historical median P/S.
Fair value ≈ $14.99 · price $23.80 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$CAPR Covid vaccine study has been updated to completed, but no results posted yet. I will be interesting to hear more. https://clinicaltrials.gov/study/NCT07095231?term=Capricor&viewType=Card&rank=2&tab=history&a=30&b=31#version-content-panel
View on StockTwits ↗$CAPR FDA chooses the following for pilot program, hopefully it can help CAPR in the future
View on StockTwits ↗$CAPR still not sure why they would present the data like this. The trend line is not representative of the aggregate whole nor the population without the low performers. It shows an increase of heart eff from year 4 to year 5. Seeing this type of statistical misrepresentation is concerning. Is this analysis done by capr? Or a stastical consulting company?
View on StockTwits ↗$CAPR very frustrating that a fuckin adcom news release can drop the stock 20% in two trading days. Back to where we were in January. Should be going up with approval 6 weeks away.
View on StockTwits ↗$CAPR perfect timing for Capricor stock. Buy when others are in fear!!
View on StockTwits ↗$CAPR perfect storm: Russel 3000 rebancing and selling automatically on the day we have news about ad com. Shorts celebrating. Funds rebalancing all the time especially small caps.
View on StockTwits ↗$SLS this is another L for bears steve. Just like $CAPR Nfa. Gla.
View on StockTwits ↗$CAPR There are a lot of newbies looking at Capricor. You may want start your dd by looking at this. https://d1io3yog0oux5.cloudfront.net/_bba9ebf3a0a1b30f24671fe13fb8fe35/capricor/db/2227/21534/pdf/CAPR+May+2026+%28Deck%29.pdf
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.